Please use this identifier to cite or link to this item:
|Title:||Inhibitors of plasmodial serine hydroxymethyltransferase (SHMT): Cocrystal structures of pyrazolopyrans with potent blood- and liver-stage activities|
|Authors:||Matthias C. Witschel|
Laura M. Sanz-Alonso
Swiss Tropical and Public Health Institute (Swiss TPH)
Thailand National Center for Genetic Engineering and Biotechnology
California Institute for Biomedical Research
GlaxoSmithKline plc, Spain
Monash Institute of Pharmaceutical Sciences
|Keywords:||Biochemistry, Genetics and Molecular Biology|
|Citation:||Journal of Medicinal Chemistry. Vol.58, No.7 (2015), 3117-3130|
|Abstract:||© 2015 American Chemical Society. Several of the enzymes related to the folate cycle are well-known for their role as clinically validated antimalarial targets. Nevertheless for serine hydroxymethyltransferase (SHMT), one of the key enzymes of this cycle, efficient inhibitors have not been described so far. On the basis of plant SHMT inhibitors from an herbicide optimization program, highly potent inhibitors of Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) SHMT with a pyrazolopyran core structure were identified. Cocrystal structures of potent inhibitors with PvSHMT were solved at 2.6 Å resolution. These ligands showed activity (IC50/EC50 values) in the nanomolar range against purified PfSHMT, blood-stage Pf, and liver-stage P. berghei (Pb) cells and a high selectivity when assayed against mammalian cell lines. Pharmacokinetic limitations are the most plausible explanation for lack of significant activity of the inhibitors in the in vivo Pb mouse malaria model.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.